Claritev Announces Q3 EPS of $4.23 Compared to ($24.25) in the Previous Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Q3 Financial Performance: Claritev reported Q3 revenue of $245.96 million, an increase from $230.50 million the previous year, and ended the quarter with $39.2 million in unrestricted cash and cash equivalents.
Strategic Focus: The company declared 2025 as the "Year of the Turn," indicating a shift in strategy towards growth and execution of their Strategic Plan, referred to as "The Way Up."
Commitment to Healthcare: CEO Travis Dalton emphasized the company's mission to make healthcare affordable and transparent, highlighting the importance of building relationships within the healthcare ecosystem.
Future Outlook: Claritev's increased full-year guidance reflects confidence in their strategic direction and the foundation laid for future success.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTEV
Wall Street analysts forecast CTEV stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 24.560
Low
33.00
Averages
62.00
High
90.00
Current: 24.560
Low
33.00
Averages
62.00
High
90.00
About CTEV
Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Major Wall Street Rating Changes Overview
- Dell Upgrade: Susquehanna upgraded Dell from neutral to positive, citing increased confidence in a sustainable 8-10% operating margin and a 6% free cash flow margin, which supports a potential rerating of its EV/sales multiple to 3x, indicating strong market potential.
- Viper Energy Initiation: RBC initiated coverage of Viper Energy with an Outperform rating and a $58 price target, highlighting its advantages in scale and core Permian focus, positioning it as a best-in-class mineral and royalty company.
- SentinelOne Buy Rating: Bank of America upgraded SentinelOne from neutral to buy, viewing its solid quarterly performance as a strong entry point after an 18% decline in after-hours trading, reflecting confidence in its future growth prospects.
- XPeng Upgrade: Macquarie upgraded XPeng from neutral to outperform, noting its volume growth in the Chinese EV market, while future investments in humanoids and robotaxis provide additional upside potential for its stock.
See More
Claritev Corporation Faces Antitrust Investigation
- Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on its Data iSight pricing tool, which may violate federal securities laws, potentially impacting the company's reputation and operations.
- Significant Stock Price Drop: Following the investigation news, Claritev's stock plummeted from $23.47 to $13.87 per share, a 41% decline, directly reflecting market uncertainty regarding the company's future and a loss of investor confidence.
- Law Firm Involvement: Kirby McInerney LLP is investigating on behalf of Claritev investors to assess the potential for legal claims, indicating heightened scrutiny of the company's senior management's possible misconduct and the implications for shareholder interests.
- Investor Rights Protection: Although no lawsuit has been filed yet, Kirby McInerney LLP encourages all investors who purchased or acquired Claritev securities to reach out to discuss their rights, emphasizing the necessity and urgency of legal support in light of the ongoing investigation.
See More
Claritev Corporation Faces Antitrust Investigation
- Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on its Data iSight pricing tool, which may violate federal securities laws, impacting the company's reputation and market trust.
- Significant Stock Price Drop: Following the investigation news, Claritev's stock plummeted from $23.47 per share on May 14 to $13.87 on May 15, representing a 41% decline, which directly affects investor confidence and may lead to subsequent lawsuits.
- Law Firm Involvement: Kirby McInerney LLP has reminded Claritev investors of the ongoing investigation to determine if claims can be filed, indicating the company faces legal risks that could affect its future operations.
- Investor Rights Protection: The firm encourages investors who purchased or acquired Claritev securities to contact them to discuss their rights, highlighting the importance of investor protection and potentially impacting the company's future investment appeal.
See More
Claritev Faces Antitrust Investigation Amid Stock Drop
- Antitrust Investigation Launched: The U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev on May 14, 2026, focusing on its Data iSight pricing tool, which may expose the company to legal liabilities.
- Significant Stock Drop: Following the investigation news, Claritev's stock plummeted from $23.47 per share on May 14 to $13.87 on May 15, marking a 41% decline, indicating market concerns about the company's future.
- Investor Rights Protection: Bragar Eagel & Squire is representing Claritev shareholders in investigating potential claims, urging affected investors to contact the firm to discuss their legal rights, highlighting the importance of investor advocacy.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its extensive experience in handling similar cases.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Healthcare Stocks Rise Slightly on NYSE
- Healthcare Index Increase: The NYSE Healthcare Index rose by 0.4% on Monday afternoon, indicating a rebound in market confidence towards the healthcare sector, likely influenced by optimistic investor expectations regarding future healthcare policies.
- Market Trend Analysis: The upward trend in healthcare stocks suggests that despite economic uncertainties, investors remain bullish on the long-term growth potential of the healthcare industry, particularly in the context of new drug development and an aging population.
- Improved Investor Sentiment: The stable performance of healthcare stocks has led to improved investor sentiment, which may result in increased capital inflows into the sector, further driving the rise in healthcare stocks.
- Industry Outlook: The ongoing growth in the healthcare sector is likely to attract more investor attention, especially with the dual support of policy backing and technological innovation, indicating that more investment opportunities are expected to emerge in the future.
See More
Major Wall Street Rating Changes Overview
- Dell Upgrade: Susquehanna upgraded Dell from neutral to positive, citing increased confidence in a sustainable 8-10% operating margin and a 6% free cash flow margin, which supports a potential rerating of its EV/sales multiple to 3x, indicating strong market potential.
- Viper Energy Initiation: RBC initiated coverage of Viper Energy with an Outperform rating and a $58 price target, highlighting its advantages in scale and core Permian focus, positioning it as a best-in-class mineral and royalty company.
- SentinelOne Buy Rating: Bank of America upgraded SentinelOne from neutral to buy, viewing its solid quarterly performance as a strong entry point after an 18% decline in after-hours trading, reflecting confidence in its future growth prospects.
- XPeng Upgrade: Macquarie upgraded XPeng from neutral to outperform, noting its volume growth in the Chinese EV market, while future investments in humanoids and robotaxis provide additional upside potential for its stock.
See More
Claritev Corporation Faces Antitrust Investigation
- Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on its Data iSight pricing tool, which may violate federal securities laws, potentially impacting the company's reputation and operations.
- Significant Stock Price Drop: Following the investigation news, Claritev's stock plummeted from $23.47 to $13.87 per share, a 41% decline, directly reflecting market uncertainty regarding the company's future and a loss of investor confidence.
- Law Firm Involvement: Kirby McInerney LLP is investigating on behalf of Claritev investors to assess the potential for legal claims, indicating heightened scrutiny of the company's senior management's possible misconduct and the implications for shareholder interests.
- Investor Rights Protection: Although no lawsuit has been filed yet, Kirby McInerney LLP encourages all investors who purchased or acquired Claritev securities to reach out to discuss their rights, emphasizing the necessity and urgency of legal support in light of the ongoing investigation.
See More
Claritev Corporation Faces Antitrust Investigation
- Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on its Data iSight pricing tool, which may violate federal securities laws, impacting the company's reputation and market trust.
- Significant Stock Price Drop: Following the investigation news, Claritev's stock plummeted from $23.47 per share on May 14 to $13.87 on May 15, representing a 41% decline, which directly affects investor confidence and may lead to subsequent lawsuits.
- Law Firm Involvement: Kirby McInerney LLP has reminded Claritev investors of the ongoing investigation to determine if claims can be filed, indicating the company faces legal risks that could affect its future operations.
- Investor Rights Protection: The firm encourages investors who purchased or acquired Claritev securities to contact them to discuss their rights, highlighting the importance of investor protection and potentially impacting the company's future investment appeal.
See More
Claritev Faces Antitrust Investigation Amid Stock Drop
- Antitrust Investigation Launched: The U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev on May 14, 2026, focusing on its Data iSight pricing tool, which may expose the company to legal liabilities.
- Significant Stock Drop: Following the investigation news, Claritev's stock plummeted from $23.47 per share on May 14 to $13.87 on May 15, marking a 41% decline, indicating market concerns about the company's future.
- Investor Rights Protection: Bragar Eagel & Squire is representing Claritev shareholders in investigating potential claims, urging affected investors to contact the firm to discuss their legal rights, highlighting the importance of investor advocacy.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, demonstrating its extensive experience in handling similar cases.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Healthcare Stocks Rise Slightly on NYSE
- Healthcare Index Increase: The NYSE Healthcare Index rose by 0.4% on Monday afternoon, indicating a rebound in market confidence towards the healthcare sector, likely influenced by optimistic investor expectations regarding future healthcare policies.
- Market Trend Analysis: The upward trend in healthcare stocks suggests that despite economic uncertainties, investors remain bullish on the long-term growth potential of the healthcare industry, particularly in the context of new drug development and an aging population.
- Improved Investor Sentiment: The stable performance of healthcare stocks has led to improved investor sentiment, which may result in increased capital inflows into the sector, further driving the rise in healthcare stocks.
- Industry Outlook: The ongoing growth in the healthcare sector is likely to attract more investor attention, especially with the dual support of policy backing and technological innovation, indicating that more investment opportunities are expected to emerge in the future.
See More
